Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-5933 tablets plus CT-707 tablets in KRAS G12C-mutant advanced solid tumors (Ib/II)
CTR20251745Phase 2Active
- Sponsor
- Shouyao Holdings
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SY-5933 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), sponsored by Shouyao Holdings. Started Jul 2025; status: active.
02
Drugs
SY-5933
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20251745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251745.